Cutter & CO Brokerage Inc. Has $195,000 Position in Galectin Therapeutics Inc. (NASDAQ:GALT)

Cutter & CO Brokerage Inc. decreased its position in shares of Galectin Therapeutics Inc. (NASDAQ:GALT) by 9.3% during the 4th quarter, Holdings Channel reports. The institutional investor owned 117,488 shares of the company’s stock after selling 12,000 shares during the quarter. Cutter & CO Brokerage Inc.’s holdings in Galectin Therapeutics were worth $195,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of GALT. Retirement Guys Formula LLC raised its position in shares of Galectin Therapeutics by 87.0% during the fourth quarter. Retirement Guys Formula LLC now owns 21,500 shares of the company’s stock worth $36,000 after acquiring an additional 10,000 shares during the last quarter. Beacon Capital Management LLC increased its position in Galectin Therapeutics by 89.6% in the fourth quarter. Beacon Capital Management LLC now owns 23,905 shares of the company’s stock worth $40,000 after purchasing an additional 11,300 shares during the period. AE Wealth Management LLC grew its position in shares of Galectin Therapeutics by 72.7% during the 3rd quarter. AE Wealth Management LLC now owns 26,841 shares of the company’s stock worth $52,000 after buying an additional 11,300 shares during the period. Finally, D.A. Davidson & CO. raised its stake in shares of Galectin Therapeutics by 15.2% during the third quarter. D.A. Davidson & CO. now owns 37,825 shares of the company’s stock worth $73,000 after buying an additional 5,000 shares during the last quarter. 11.68% of the stock is currently owned by institutional investors.

Galectin Therapeutics Price Performance

Shares of GALT traded down $0.10 during trading hours on Wednesday, reaching $3.28. The stock had a trading volume of 110,740 shares, compared to its average volume of 129,583. Galectin Therapeutics Inc. has a 52 week low of $1.28 and a 52 week high of $4.27. The firm has a 50-day moving average of $2.51 and a 200 day moving average of $2.09.

Analysts Set New Price Targets

A number of brokerages have issued reports on GALT. StockNews.com raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a report on Tuesday, April 9th.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.